[{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"PT00114","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Protagenic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagenic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Protagenic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Phytanix Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Peptide","year":"2025","type":"Merger","leadProduct":"PT-00114","moa":"CRH","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Protagenic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagenic Therapeutics \/ Phytanix Bio","highestDevelopmentStatusID":"7","companyTruncated":"Protagenic Therapeutics \/ Phytanix Bio"},{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Phytanix Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Peptide","year":"2025","type":"Merger","leadProduct":"PT-00114","moa":"CRH","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Protagenic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagenic Therapeutics \/ Phytanix Bio","highestDevelopmentStatusID":"7","companyTruncated":"Protagenic Therapeutics \/ Phytanix Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Protagenic Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The combined entity, to be called Phytanix, Inc, will bring together two pipelines focused on stress-related and CNS disorders such as PT-00114, is being evaluated for Treatment-Resistant Depression.

                          Product Name : PT-00114

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          May 21, 2025

                          Lead Product(s) : PT-00114

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Phytanix Bio

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The combined entity, to be called Phytanix, Inc, will bring together two pipelines focused on stress-related and CNS disorders such as PT-00114, is being evaluated for Treatment-Resistant Depression.

                          Product Name : PT-00114

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          May 19, 2025

                          Lead Product(s) : PT-00114

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Phytanix Bio

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The capital will be used to complete the last remaining components of the Company’s investigational New Drug (IND) filing with the FDA for its lead drug compound, PT00114, known scientifically as teneurin C-terminal associated peptide (TCAP).

                          Product Name : PT00114

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          August 09, 2020

                          Lead Product(s) : PT00114

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : $2.0 million

                          Deal Type : Financing

                          blank